Inventor
LEE E-CHIANG
GB48 patents
⚠️ This page may combine multiple inventors who share the name “LEE E-CHIANG”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
KYMAB LTD
38 patentsUS9505827B2Nov 29, 2016
Animal models and therapeutic molecules
KYMAB LTD27 citations98
US9434782B2Sep 6, 2016
Animal models and therapeutic molecules
KYMAB LTD31 citations98
US9938358B2Apr 10, 2018
Animal models and therapeutic molecules
KYMAB LTD19 citations94
US9938357B2Apr 10, 2018
Animal models and therapeutic molecules
KYMAB LTD21 citations94
US9924705B2Mar 27, 2018
Animal models and therapeutic molecules
KYMAB LTD20 citations94
US9896516B2Feb 20, 2018
Animal models and therapeutic molecules
KYMAB LTD20 citations94
US10165763B2Jan 1, 2019
Animal models and therapeutic molecules
KYMAB LTD13 citations93
US10149462B2Dec 11, 2018
Animal models and therapeutic molecules
KYMAB LTD15 citations93
US10064398B2Sep 4, 2018
Animal models and therapeutic molecules
KYMAB LTD14 citations93
US9957323B2May 1, 2018
Anti-ICOS antibodies
KYMAB LTD27 citations92
US9788534B2Oct 17, 2017
Animal models and therapeutic molecules
KYMAB LTD18 citations92
US9783593B2Oct 10, 2017
Antibodies, variable domains and chains tailored for human use
KYMAB LTD19 citations91
US10966412B2Apr 6, 2021
Animal models and therapeutic molecules
KYMAB LTD11 citations86
US10774155B2Sep 15, 2020
Animal models and therapeutic molecules
KYMAB LTD9 citations84
US10667501B2Jun 2, 2020
Transgenic non-human vertebrate for the in vivo production of dual specificity immunoglobulins or hypermutated heavy chain only immunoglobulins
KYMAB LTD15 citations84
US10226033B2Mar 12, 2019
Animal models and therapeutic molecules
KYMAB LTD13 citations84
US9963716B2May 8, 2018
Chimaeric surrogate light chains (SLC) comprising human VpreB
KYMAB LTD12 citations83
US9783618B2Oct 10, 2017
Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
KYMAB LTD17 citations83
US10730930B2Aug 4, 2020
Antibodies, variable domains and chains tailored for human use
KYMAB LTD9 citations82
US10815308B2Oct 27, 2020
FIXaxFX bispecific antibody with common light chain
KYMAB LTD6 citations80
US11606941B2Mar 21, 2023
Animal models and therapeutic molecules
KYMAB LTD1 citations73
US11564380B2Jan 31, 2023
Animal models and therapeutic molecules
KYMAB LTD1 citations73
US11399522B2Aug 2, 2022
Animal models and therapeutic molecules
KYMAB LTD2 citations73
US11051497B2Jul 6, 2021
Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
KYMAB LTD5 citations72
US10337000B2Jul 2, 2019
Expression vector production and high-throughput cell screening
KYMAB LTD4 citations72
US11976135B2May 7, 2024
FIXaxFX bispecific antibody with common light chain
KYMAB LTD3 citations71
US11858996B2Jan 2, 2024
Anti-ICOS antibodies
KYMAB LTD2 citations68
US11371042B2Jun 28, 2022
Expression vector production and high-throughput cell screening
KYMAB LTD0 citations62
US11297810B2Apr 12, 2022
Animal models and therapeutic molecules
KYMAB LTD1 citations62
US11820810B2Nov 21, 2023
Antibodies, variable domains and chains tailored for human use
KYMAB LTD0 citations61
US11812731B2Nov 14, 2023
Animal models and therapeutic molecules
KYMAB LTD0 citations61
US11919969B2Mar 5, 2024
Bispecific antibodies for factor IX and factor X
KYMAB LTD1 citations59
US11440960B2Sep 13, 2022
TIGIT antibodies, encoding nucleic acids and methods of using said antibodies in vivo
KYMAB LTD1 citations56
US12473378B2Nov 18, 2025
Antigen-binding molecules comprising unpaired variable domains
KYMAB LTD0 citations53
US11707056B2Jul 25, 2023
Animals, repertoires and methods
KYMAB LTD0 citations52
US11920128B2Mar 5, 2024
Methods, cells and organisms
KYMAB LTD0 citations50
US12384855B2Aug 12, 2025
PCSK9 antagonists
KYMAB LTD0 citations46
US12435134B2Oct 7, 2025
Antagonists anti-CD7 antibodies
KYMAB LTD0 citations42